Amgen Seeks High Court Review Of Investor Class Cert.
Amgen Inc. asked the U.S. Supreme Court last week to review the Ninth Circuit's refusal to decertify a class of shareholders who allege Amgen misled investors about two top-selling anemia drugs,...To view the full article, register now.
Already a subscriber? Click here to view full article